I'm not up on the respiratory space but it seems uber competitive this looks like a threat to GSK's Trelegy Ellipta which they have been counting on to make up for the loss of advair GSK also has REGN and AZN breathing down their neck for eosinophilic asthma w nucala
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.